Cardiac fibrosis is the pathological accumulation of extracellular matrix proteins in the heart, a process orchestrated primarily by fibroblasts. When the heart is stressed by pressure overload, myocardial infarction, or chronic inflammation, quiescent fibroblasts activate into myofibroblasts, cells that proliferate, migrate, contract, and deposit large quantities of collagen and other matrix components. In the short term this response is protective, patching damaged tissue and preserving the structural integrity of the ventricular wall. When the signal never shuts off, however, the accumulating scar stiffens the myocardium, impairs electrical conduction, and gradually pushes the heart toward diastolic dysfunction and heart failure. Clinically, no approved therapy directly targets this process; existing treatments manage hemodynamic load and neurohormonal activation while fibrosis progresses.

PTBP1, polypyrimidine tract binding protein 1, is one of the cell’s most influential splicing factors. Alternative splicing allows a single gene to yield multiple protein isoforms by including or excluding different RNA segments, and PTBP1 binds specific sequence motifs on precursor messenger RNA to tip these decisions. Beyond splicing, PTBP1 participates in RNA stability, translation, and even transcript localization, and it is famous in regenerative biology for its ability, when silenced, to help convert non-neuronal cells into neuron-like cells. Its role in the heart’s fibrotic armory, however, has been far less clear, and the new study set out to test whether fibroblast PTBP1 is a bystander or an active participant in scarring.

To resolve that question, the investigators generated mice in which PTBP1 was deleted selectively in cardiac fibroblasts, sidestepping the developmental and neuronal roles of the protein that complicate whole-animal knockout approaches. This cell-type-specific strategy is essential because PTBP1 is broadly expressed; removing it everywhere would produce a tangle of secondary effects impossible to attribute to fibroblasts. With the deletion restricted to the scar-forming population, the researchers could ask a clean question: when fibroblasts lose their master splicing regulator, does the fibrotic response to cardiac stress change, and if so, how?

The answer was yes, and the mechanism was legible at the level of the transcriptome. Fibroblasts lacking PTBP1 showed broad alterations in alternative splicing, and among the affected transcripts were genes central to the profibrotic program. The splice isoforms produced in the knockout cells differed from those made in wild-type fibroblasts in ways that modulated the cells’ sensitivity to the cytokine TGF-beta, the dominant driver of myofibroblast differentiation, and to the downstream signaling that activates collagen production and contractility. In effect, removing the splicing factor rewired the interpretive layer between the fibrotic signals a cell receives and the proteins it deploys in response.

This outcome matters conceptually because much of fibrosis research has concentrated on transcriptional control, asking which transcription factors activate fibrotic genes and which signaling cascades converge on their promoters. The PTBP1 data demonstrate that post-transcriptional regulation constitutes a second, largely independent control layer. A gene can be transcribed at a normal rate yet produce a protein with altered function if its exons are assembled differently. In fibroblasts, that assembly step is influenced heavily by PTBP1, meaning the intensity and character of the scarring response can be tuned without changing gene expression in the conventional sense.

Technically, the study illustrates the current standard toolkit for dissecting splicing in vivo. RNA sequencing of fibroblasts isolated from control and knockout animals allowed the team to quantify splicing changes genome-wide, identifying skipped exons, alternative splice sites, and shifted isoform ratios across thousands of transcripts. These molecular maps were then connected to cellular phenotypes measured in culture and to the intact organ in models of cardiac stress, an approach that links a molecular event, exon usage, all the way through to tissue-level consequences. It is exactly this chain of evidence, from factor to isoform to cell behavior to organ pathology, that turns a correlation into a credible regulatory mechanism.

One of the most interesting implications concerns isoform switching as a therapeutic concept. If individual fibrotic genes exist in profibrotic and less-pathological isoforms, then future interventions might not need to silence a gene outright, which is often toxic because genes rarely have a single role. Instead, drugs could be designed to nudge splicing decisions toward protective isoforms. Splice-switching oligonucleotides, short synthetic molecules that bind pre-mRNA and redirect the splicing machinery, are already approved for neuromuscular disease and are being explored in cardiology. A validated role for PTBP1 in the fibrotic response provides a concrete molecular handle for that class of strategy in heart disease.

The work also adds to a growing literature on RNA-binding proteins as disease genes. Over the past decade, RNA processing factors have been implicated in cardiomyopathy, congenital heart disease, and cardiac aging, but fibroblasts have received less attention than cardiomyocytes in this respect. Given that fibroblasts compose the majority of non-muscle cells in the heart and are the chief effectors of remodeling, the demonstration that a single splicing factor modulates their pathological activation suggests that the post-transcriptional biology of these cells is a rich and underexplored therapeutic landscape.

Important caveats remain. PTBP1 is a pleiotropic regulator, and changing its dosage in fibroblasts will inevitably affect many targets, some beneficial and some not; translating the finding into a therapy will require identifying the specific isoform switches that carry the antifibrotic effect and finding selective ways to control them. Dose, timing, and cell-type specificity will all need careful optimization, and the long-term consequences of altering fibroblast splicing in a chronically stressed heart are unknown. Nevertheless, the study delivers a clear and consequential message: the heart’s scarring response is governed not only by which profibrotic genes are expressed, but by how their RNA is edited, and a single RNA-binding protein helps call those shots. In a field where therapeutic options for fibrosis remain limited, that is a lead worth pursuing.

Subject of Research: Role of the splicing factor PTBP1 in cardiac fibroblast profibrotic activation and alternative splicing.

Article Title: Cardiac fibroblast deletion of PTBP1 modulates the profibrotic response by alternative splicing

Article References: Ricketts, S. N., Farber, G. M., Verma, S. K., Dong, Y., Xie, Y., Takasugi, P. R., Chen, S., Du, L., Wang, H., Hui, W., Keles, C., Tsoy, S., Fuller, G., Wang, M., Gentile, G. M., Giudice, J., Kuyumcu-Martinez, M. N., Liu, J., & Qian, L. (2026). Cardiac fibroblast deletion of PTBP1 modulates the profibrotic response by alternative splicing. Nature Communications. https://doi.org/10.1038/s41467-026-77609-7

Image Credits: AI Generated

DOI: 10.1038/s41467-026-77609-7

Keywords: PTBP1, cardiac fibroblasts, alternative splicing, cardiac fibrosis, TGF-beta, RNA-binding protein, myofibroblast, heart failure, splicing factors, extracellular matrix, Cardiac, fibroblast

Psoriasis is a multifactorial autoimmune disorder hallmarked by hyperproliferative keratinocytes and a hyperactive immune milieu. While much attention has centered on immune cells such as T cells and dendritic cells in driving the pathology, the stromal compartment’s contributions have remained relatively obscure. The present study compellingly positions CD73^high fibroblasts as sentinel architects that modulate keratinocyte behavior and immune cell recruitment through finely tuned enzymatic and signaling cascades, thereby reprogramming the psoriatic microenvironment.

CD73, or ecto-5′-nucleotidase, functions enzymatically to convert AMP to adenosine, a critical immunomodulatory molecule frequently implicated in inflammation and tissue repair. The team’s extensive immunophenotyping revealed a distinct population of fibroblasts exhibiting elevated CD73 expression specifically within psoriatic lesions compared to healthy skin. Spatial transcriptomics further demonstrated that these fibroblasts reside in close apposition to lesional keratinocytes, suggesting a direct paracrine interaction facilitating inflammatory feedback loops.

Mechanistically, CD73^high fibroblasts potentiate keratinocyte inflammatory responses by modulating extracellular adenosine levels, which in turn engage adenosine receptors on epidermal cells and resident immune populations. This adenosine-rich environment promotes release of proinflammatory cytokines such as IL-17A, IL-22, and TNF-α, which are well-established drivers of keratinocyte hyperproliferation and aberrant differentiation — hallmark features of psoriatic plaques. Intriguingly, pharmacologic inhibition of CD73 enzymatic activity attenuated these inflammatory signatures in ex vivo psoriatic skin cultures, underscoring the functional relevance of this pathway.

Further elucidation revealed that CD73^high fibroblasts actively influence immune cell composition within the epidermal niche by secreting chemokines that recruit pathogenic Th17 cells and neutrophils, perpetuating a vicious cycle of inflammation. This fibroblast-mediated orchestration of immune infiltration challenges the traditional immune-centric models of psoriasis and implicates stromal cells as critical drivers of chronic disease maintenance and progression.

The researchers harnessed cutting-edge single-cell RNA sequencing coupled with multiplexed immunofluorescence imaging to precisely delineate the phenotypic heterogeneity and spatial dynamics of fibroblast subsets. Notably, the CD73^high fibroblast population exhibited a proinflammatory transcriptomic signature distinct from canonical fibroblasts, including upregulation of matrix metalloproteinases and adhesion molecules, facilitating tissue remodeling and leukocyte extravasation within lesional skin.

Importantly, these findings bear clinical implications far beyond mechanistic novelty. Targeted inhibition of CD73 or modulation of fibroblast-derived adenosine signaling could represent a novel class of therapeutics to disrupt the self-amplifying inflammatory circuits in psoriasis. Unlike current biologics that primarily target immune cells, stromal-directed therapies may offer complementary or synergistic benefits, particularly for patients refractory to existing treatments. The authors advocate for the development of small molecules or monoclonal antibodies capable of selectively modulating CD73 activity to restore epidermal homeostasis.

This investigation also prompts a reevaluation of fibroblast functions across other chronic inflammatory and autoimmune disorders. The concept of “inflammatory fibroblasts” with distinct enzymatic profiles potentially extends to rheumatoid arthritis, inflammatory bowel disease, and beyond, suggesting conserved mechanisms by which stromal niches sustain pathogenic immune responses. In this light, fibroblasts emerge not merely as passive bystanders but as active immunologic architects in diverse tissues.

Technically, the study leveraged innovative in vitro coculture systems combining patient-derived psoriatic fibroblasts and keratinocyte lines, recapitulating key inflammatory hallmarks in a controlled environment. Gain- and loss-of-function experiments targeting CD73 elucidated causality, while proteomic analyses of fibroblast secretomes identified candidate mediators responsible for the keratinocyte-immune cell crosstalk. Thus, the multidisciplinary approach synthesized molecular, cellular, and systems-level insights.

The dynamic interplay between fibroblasts and keratinocytes revealed in this research underscores a paradigm shift in the conceptualization of epithelial immune microenvironments. Instead of viewing keratinocytes as mere targets of immune assault, this study positions them as integral components dynamically regulated by stromal enzymatic activities that modulate local adenosine concentrations and signaling. Such nuanced understanding enriches the foundation for next-generation biomarker discovery.

Looking forward, in vivo validation using psoriatic animal models expressing conditional CD73 knockouts will be essential to confirm the therapeutic potential observed ex vivo. Furthermore, longitudinal patient studies assessing correlations between fibroblast CD73 expression levels and clinical disease severity could refine prognostic criteria and guide personalized medicine approaches. Given the heterogeneity in psoriasis phenotypes, stratifying patients based on stromal fibroblast activity might optimize treatment responses.

The viral nature of these findings rapidly proliferates in dermatological and immunological circles, sparking enthusiasm about reshaping psoriasis therapy. The revelation that fibroblasts not only support skin architecture but also prime inflammatory cascades advances a holistic view of disease pathophysiology. It invigorates the search for stromal cell-targeting interventions that might deliver durable remission or even cure, a long-sought goal in chronic inflammatory skin diseases.

Ultimately, Tian and colleagues’ seminal work places CD73^high fibroblasts at the nexus of cutaneous inflammation, redefining cellular hierarchies in psoriasis. This refined model integrating enzymatic, molecular, and immunological dimensions charts a promising translational trajectory from bench to bedside. It invites the scientific community to rethink psoriasis as a disease equally mediated by dysregulated stromal-epithelial interactions, heralding a new era in dermatological research and clinical management.

By elucidating the mechanistic underpinnings through state-of-the-art methodologies and comprehensive molecular profiling, this study inspires renewed optimism for developing precision therapies. The identification of metabolic enzymes such as CD73 as central regulators injects fresh momentum into the exploration of bioactive metabolites as immunomodulators within epithelial tissues. This conceptual leap fuels broad interest in epidermal biology and immune-stromal communication networks.

The implications of these discoveries extend beyond psoriasis into the broader context of inflammatory disorders where fibroblasts and epithelial cells coexist in dynamic equilibrium. Future investigations will likely explore how other fibroblast subsets with distinct molecular signatures contribute to tissue-specific pathology and regenerative processes. Such research promises to unlock systemic insights into cellular cooperation and conflict shaping human health and disease.

In conclusion, the identification of CD73^high fibroblasts as master regulators in the psoriasis-associated epithelial immune microenvironment represents a transformative advance in dermatological science. This work exemplifies how integrative, multidisciplinary approaches can uncover previously unappreciated cellular players modulating complex inflammatory diseases. As these findings gain traction, they pave the way for innovative treatments poised to alleviate the burden of psoriasis for millions worldwide.

Subject of Research: Psoriasis pathogenesis with focus on fibroblast-keratinocyte interactions and inflammatory microenvironment

Article Title: CD73^high fibroblasts orchestrate keratinocyte inflammation in the psoriasis-associated epithelial immune microenvironment

Article References:
Tian, Y., Guo, J., Sun, J. et al. CD73^high fibroblasts orchestrate keratinocyte inflammation in the psoriasis-associated epithelial immune microenvironment. Nat Commun (2026). https://doi.org/10.1038/s41467-026-71323-0

Image Credits: AI Generated